Amlodpine (active ingredient, amlodipine besilate) is indicated for adults with hypertension, chronic stable angina pectoris and vasospastic (Prinzmetal’s) angina. Indicated in paediatric patients* with hypertension from 6 – 17 years of age.
Amlodipine is available in tablet form in a 2.5mg dose for oral administration.
Adults
For both hypertension and angina the usual initial dose for adults is 5mg once daily which may be increased to a maximum dose of 10mg once daily depending on the individual patient’s response.
2.5 mg
Indication: Hypertension, chronic stable angina pectoris and vasospastic (Prinzmetal’s) angina
Suitable for Vegetarians
Suitable for Vegans
Gluten Free
Regulatory Status POM
Special populations
Paediatric patients
The recommended antihypertensive oral dose in paediatric patients ages 6-17 years is 2.5mg once daily as a starting dose, up-titrated to 5mg once daily if the blood pressure goal is not achieved after 4 weeks. Doses in excess of 5mg daily have not been studied in paediatric patients. No data available in children under 6 years of age.
Hepatically impaired patients
Dosage recommendations have not been established in mild to moderate hepatic impairment; dose selection should be cautious and should start at the lower end of the dosing range. Amlodipine should be initiated at the lowest dose and titrated slowly in severe hepatic impairment.
Renally impaired patients
Normal dosage is recommended.
Elderly patients
Normal dosage regimens are recommended in the elderly, but increase of the dosage should take place with care.
.
Contraindications
Hypersensitivity to dihydropyridines derivatives, amlodipine or any of the excipients, severe hypotension, shock (including cardiogenic shock), obstruction of the outflow tract of the left ventricle, (e.g. high grade aortic stenosis), haemodynamically unstable heart failure after acute myocardial infarction.
Please refer to the Summary of Product Characteristics for a list of adverse events, special warnings and precautions for use.
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine.
Adverse events should also be reported to Bristol Laboratories on Tel: 0044 (0) 1442 200 922 or Email: info@bristol-labs.co.uk
References
External Links
You are now leaving the Bristol Laboratories website. Bristol Laboratories is no longer responsible for the content that you are about to view. Bristol Laboratories assumes no responsibility for the website or its content.
This website is intended to provide information to UK healthcare professionals only.
By clicking on the Healthcare Professional button you are acknowledging that you are a healthcare professional in the UK and you agree to our Terms and Conditions and Privacy and Cookie Policy.
If you are a member of the general public, please click on the Member of the Public button to be directed to the Bristol Laboratories website.
Reporting side effects: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/. By reporting side effects, you can help provide more information on the safety of this medicine.
Date of Preparation May 2020 Code: BLL-001-014
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkRead more